MS: Busting the Myths
April 24, 2025 | Advocacy, Life with MS, News, Treatments
Photo by Kristine Wook, Unsplash. Medsafe have approved the registration of Ocrevus ® Subcutaneous (SC) (ocrelizumab and hyaluronidase) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The announcement on […]
October 24, 2024 | Education, Event, Progressive, Research, Webinar
On 12th July 2024 Multiple Sclerosis New Zealand (MSNZ) co-hosted our MS Brain Health seminar in Auckland with the NZ MS Research Trust and MS Auckland. Thank you to all attendees that came to hear from our special guest speaker, […]
October 15, 2024 | Media, News, Press Release, Progressive
Pharmac’s decision-making process for funding drugs in Aotearoa New Zealand is in need of a major overhaul – according to a new independent report. The Milne Report, commissioned by Multiple Sclerosis New Zealand (MSNZ), says its time Pharmac based its […]
May 29, 2024 | Life with MS, News, Progressive, Treatments
On Wednesday 15 May, Multiple Sclerosis NZ raised how critical workforce shortages are impacting patients with Primary Progressive MS (PPMS) access to time sensitive disease modifying therapies. A business case prepared by clinical specialists had been under review for five […]
May 15, 2024 | Advocacy, Funding, Life with MS, Media, News, Press Release, Treatments
A celebrated Pharmac decision late last year to fund a vital drug for many Multiple Sclerosis patients has fallen flat – with dozens being turned away for treatment due to severely stretched resources across a number of services. Multiple Sclerosis […]